JPS5856694A - Reagent for assay of antinuclear antibody - Google Patents
Reagent for assay of antinuclear antibodyInfo
- Publication number
- JPS5856694A JPS5856694A JP15066881A JP15066881A JPS5856694A JP S5856694 A JPS5856694 A JP S5856694A JP 15066881 A JP15066881 A JP 15066881A JP 15066881 A JP15066881 A JP 15066881A JP S5856694 A JPS5856694 A JP S5856694A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- reagent
- insolubilized
- antinuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 36
- 230000003460 anti-nuclear Effects 0.000 title claims abstract description 27
- 238000003556 assay Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 claims abstract description 43
- 102000036639 antigens Human genes 0.000 claims abstract description 43
- 108091007433 antigens Proteins 0.000 claims abstract description 43
- 238000002372 labelling Methods 0.000 claims abstract description 20
- 238000006243 chemical reaction Methods 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 239000004033 plastic Substances 0.000 claims abstract description 9
- 229920003023 plastic Polymers 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000003018 immunoassay Methods 0.000 claims abstract description 3
- 238000005259 measurement Methods 0.000 claims description 21
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000004793 Polystyrene Substances 0.000 abstract description 2
- 229920002223 polystyrene Polymers 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010029719 Nonspecific reaction Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000005497 microtitration Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101150104365 Tomt gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- -1 sodium nitride Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は抗核抗体のエンザイムノアツセイに用いる測定
試薬に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a measuring reagent used in enzyme assay for antinuclear antibodies.
抗核抗体、なかでも抗二本鎖DNA抗体は代表的自己免
疫疾患である全身性エリテマトーデス(以下SLEとい
う)の発症と密接な関連性が予測されている。また抗二
本鎖DNA抗体の他に抗ポIJ A D P −IJボ
ース抗体の存在が明らかにされSLE患者などに高頻度
に検出されることが実証された。ボIJ A D P
−!JボースはDNA合成の調節、細胞の分化及びDN
Aの修復と密接に関連していることが知られている。ポ
IJ A D P −IJボースに対する自然抗体がS
LHに高頻度で出現することは抗ポリADP−リボース
抗体がSLEの病態及びその修飾に密接に関係している
ことを示唆する。したがってこれら抗核抗体の測定方法
が開発されている。Anti-nuclear antibodies, especially anti-double-stranded DNA antibodies, are predicted to be closely related to the onset of systemic lupus erythematosus (hereinafter referred to as SLE), which is a typical autoimmune disease. Furthermore, in addition to anti-double-stranded DNA antibodies, the existence of anti-PoIJ ADP-IJ Bose antibodies was revealed, and it was demonstrated that they are frequently detected in SLE patients. Bo IJ ADP
-! J-bose regulates DNA synthesis, cell differentiation and DNA
It is known that it is closely related to the repair of A. PoIJ ADP - Natural antibodies against IJ Bose are S
The high frequency of appearance in LH suggests that anti-polyADP-ribose antibodies are closely related to the pathology of SLE and its modification. Therefore, methods for measuring these antinuclear antibodies have been developed.
抗核抗体の測定方法としてはその感度および定量性の点
よりラジオイムノアッセイ(以下RIAという)が多く
用いられている。しかしRIAによる測定は放射性物質
を取扱うため法的に許可された施設以外ではこれを行な
うことができずその普及を妨げている。Radioimmunoassay (hereinafter referred to as RIA) is often used as a method for measuring antinuclear antibodies due to its sensitivity and quantitative nature. However, measurements by RIA cannot be carried out outside of facilities that are legally permitted to handle radioactive materials, which has hindered its widespread use.
このように使用に制約のあるRIAに代えて、標識剤と
してラジオアイソトープの代りに酵素を用いるエンザイ
ムイムノアツセイ(以下EIAという)が開発され各分
野で普及しつつある。しかし抗核抗体の測定、特に抗ボ
IJ A D P−IJボースの測定はその事例に乏し
く、EIAによる分析方法の開発が望まれている。In place of RIA, which has such restrictions on use, enzyme immunoassays (hereinafter referred to as EIA), which use enzymes instead of radioisotopes as labeling agents, have been developed and are becoming popular in various fields. However, the measurement of antinuclear antibodies, especially the measurement of anti-IJ ADP-IJ Bose, is lacking in examples, and there is a desire to develop an analysis method using EIA.
RIAおよびEIAは標識剤を異にする以外は同じ原理
に基すきその方法は大別すれば競争法とサンドインチ法
に分れるが、抗核抗体の分析には後者の方法が適してい
る。ま斥これらの方法において、抗原抗体反応により生
成した結合物を反応系よ多分離することを容易にするた
め試薬として抗原又は抗体を固体担体に結合させた固相
試薬を用いる固相法が操作の簡便さの点で勝れている。RIA and EIA are based on the same principle except for using different labeling agents, and their methods can be roughly divided into competition method and sandwich method, and the latter method is suitable for analyzing antinuclear antibodies. However, in these methods, a solid phase method using a solid phase reagent in which an antigen or antibody is bound to a solid support as a reagent is used to facilitate the separation of the bound products produced by the antigen-antibody reaction from the reaction system. It is superior in terms of simplicity.
本発明者はかかる見地より固相試掌を用いるサンドイツ
チ法による抗核抗体の測定について研究し本発明に到達
した。From this perspective, the present inventors conducted research on the measurement of antinuclear antibodies by the Sand-Deutsch method using a solid-phase probe, and arrived at the present invention.
本発明は抗核抗体のEIAによる測定用試薬において測
定対象である抗核抗体の産生を惹起する抗原をグラスチ
ック担体に1結合せしめた不溶化抗原と該抗原には特異
反応をせず測定対象である抗核抗体と特異反応をする第
二の抗体又はプロティンAに酵素を結合せしめた標識試
薬との組み合わせよりなることを特徴とする抗核抗体測
定用試薬に関する。The present invention is a reagent for measuring antinuclear antibodies by EIA, in which an antigen that induces the production of the antinuclear antibody to be measured is bonded to a plastic carrier, and an insolubilized antigen is bonded to the insoluble antigen, which does not react specifically with the antigen and does not react with the antigen to be measured. The present invention relates to a reagent for measuring an anti-nuclear antibody, characterized in that it is composed of a second antibody that specifically reacts with a certain anti-nuclear antibody, or a labeling reagent in which an enzyme is bound to protein A.
さらtで詳細に説明すれば、抗ボ!j A D P −
!jボース抗体、抗二本鎖DNA抗体などの抗核抗体の
EIAによる測定において、測定対象である抗核抗体と
免疫反応すべき相手方試薬として該抗核抗体産生を惹起
するポ’J A D P−リボース、DNAなどの抗原
をポリスチレンなどのプラスチック担体と結合せしめた
不溶化抗原をその試薬とし、さらに通常のサンドインチ
法で採用される該抗原を、酵素で標識した標識抗原に代
え、該抗原とは特異反応をせず測定対象とは特異反応を
する第二の抗体又はプロティンAを酵素で標識した試薬
を組み合わせて使用する抗核抗体測定用試薬である。If you explain it in detail in T, it will be anti-Bo! j ADP −
! In the measurement of antinuclear antibodies such as j-bose antibody and anti-double-stranded DNA antibody by EIA, the antinuclear antibody that is the object of measurement is used as a partner reagent to cause the antinuclear antibody production. - The reagent is an insolubilized antigen made by bonding an antigen such as ribose or DNA to a plastic carrier such as polystyrene, and the antigen used in the usual sandwich method is replaced with a labeled antigen labeled with an enzyme. is a reagent for measuring an antinuclear antibody that is used in combination with a second antibody that does not react specifically with the target to be measured or a reagent labeled with protein A with an enzyme.
ポリADP−リポースなどの抗原は高価なものであるた
めその効果的な使用が好ましい。プラスチックは固相担
体として特に結合剤を用いなくても抗原と結合する能力
があるが一層の効率の良い結合方法が望ましく本発明者
は鋭意研究の結果実施例1により詳述するようにプラス
チック表面をポIJ L −IJジョン前処理した後抗
原溶液と接触させこれを蒸発乾固するこ七によシブラス
チック表面((抗原を結合させる方法を用いその目的を
達することかできた。この方法によシ製造した不溶化抗
原は測定の妨害となる非特異反応が少なく良好な測定結
果が得られる。非特異反応を防止するためには通常牛血
清アルブミンを用い後処理を行なうが本発明の不溶化抗
原においては通常使用される1〜2%の濃度に比して0
005〜0.1%程度の極めて低い濃度の牛血清アルブ
ミン処理で非特異反応を防止することができる。Since antigens such as polyADP-lipose are expensive, their effective use is preferred. Although plastic has the ability to bind antigens as a solid phase carrier without the use of a specific binding agent, it is desirable to have a more efficient binding method, and as a result of extensive research, the present inventors discovered that plastic surface After pre-treating the poIJ L-IJ, the surface of the plastic surface was contacted with an antigen solution and evaporated to dryness. The insolubilized antigen produced in this way produces good measurement results with less non-specific reactions that interfere with measurements.To prevent non-specific reactions, post-treatment is usually performed using bovine serum albumin, but the insolubilized antigen of the present invention compared to the normally used concentration of 1-2%.
Non-specific reactions can be prevented by treatment with bovine serum albumin at an extremely low concentration of about 0.005 to 0.1%.
本発明の不溶化抗原に用いる固相担体としては、ポリビ
ニル、ポリアミド、ポリオレフィン、ポリエーテル、ポ
リエステル、ポリカーボネート、ポリウレタンなど各種
のプラスチックを用い得る。As the solid phase carrier used for the insolubilized antigen of the present invention, various plastics such as polyvinyl, polyamide, polyolefin, polyether, polyester, polycarbonate, and polyurethane can be used.
担体の形状としてはビーズ、ロッド、チューブなど任意
の形状のものを用い得る。近時、測定の微量化を図る目
的でマイクロタイトレージョンブレートが良く用いられ
るが本発明においても好適なものである。実施例1で示
すように300μtべの容量のマイクロタイトレージョ
ンプレートを使用し1測定当り僅かに100 nf (
2μf /mlの溶液50μt)のボIJ A D P
−IJボースの使用で測定が可能である。The carrier may be in any shape such as beads, rods, and tubes. Recently, microtightness plates are often used for the purpose of miniaturizing measurements, and they are also suitable for the present invention. As shown in Example 1, a microtitration plate with a capacity of 300 μt was used, and only 100 nf (
50μt of 2μf/ml solution)
-Measurement is possible using IJ Bose.
通常のサンドインチ法では標識試薬として不溶化抗原に
使用する抗原に標識剤を結合したものを用いるが、本発
明においては、ボIJ A D P−リボースなどの抗
原に代えて測定対象である抗核抗体とは特異的に反応す
るが該抗原とは特異反応を示さない物質に酵素を結合さ
せたものを標識試薬として用いる。このような物質とし
ては、抗免疫グロブリン抗体などの第二の抗体やプロテ
ィンAなどを用いることができる。In the normal Sand Inch method, a labeling reagent is used which is a labeling agent bound to the antigen used for the insolubilized antigen, but in the present invention, instead of an antigen such as BoIJ ADP-ribose, the antinuclear protein to be measured is used as a labeling reagent. A labeling reagent in which an enzyme is bound to a substance that reacts specifically with the antibody but not with the antigen is used. As such a substance, a second antibody such as an anti-immunoglobulin antibody, protein A, etc. can be used.
本発明の標識試薬は高価な抗原を使用しないので経済的
であるとともに標識剤である酵素の試薬中の結合量が多
く極めて高い活性を示し感度を向上させることができる
利点を有する。The labeling reagent of the present invention does not use an expensive antigen, so it is economical, and has the advantage that it has a large amount of bound enzyme, which is a labeling agent, in the reagent, exhibiting extremely high activity, and improving sensitivity.
酵素としては一般にEIAで使用されるものより選定し
て差支えないが仔牛小腸から得たアルカリフォスファタ
ーゼが活性が高く酵素基質との反応が迅速であり酵素反
応時間を10分間にまで短縮することができ極めて好適
である。本発明の標識試薬は第二の抗体又はプロティン
Aを使用するため検体中にある測定対象以外の抗体とも
結合する可能性がある。そのため不溶化抗原に非特異反
応がちシ目的外の抗体が結合する場合は測定が妨害され
る。しかし前述のよりに本発明の不溶化抗原は非特異反
応が少なく、これを組み合わせて使用することにより良
好な測定を行なうことができる。The enzyme may be selected from those commonly used in EIA, but alkaline phosphatase obtained from calf small intestine has high activity and reacts quickly with the enzyme substrate, making it possible to shorten the enzyme reaction time to 10 minutes. Very suitable. Since the labeling reagent of the present invention uses a second antibody or protein A, it may also bind to antibodies other than the measurement target present in the sample. Therefore, non-specific reactions tend to occur with the insolubilized antigen, and if an unintended antibody binds, the measurement will be interfered with. However, as mentioned above, the insolubilized antigen of the present invention has less non-specific reactions, and by using them in combination, good measurements can be made.
本発明の測定試薬を使用する抗核抗体の測定によりSL
Hの迅速な診断かり能であるのみならず、例えばリンパ
系細胞の培養により抗体を生産する過程において、培養
液を濃縮することなく容易に抗体を測定することも可能
であり極めて有益である。以下実施例及び試験例により
本発明をさらに詳細に説明するが、本発明は例に示した
抗ポIJ AD P −IJボース抗体及び抗二本鎖D
NA抗体に限定されるものでなく抗ヒストンJ’+’+
:体、抗SmK体、抗RNP抗体などの他の種類の抗咳
抗体に関してもこれを包含する。SL by measuring antinuclear antibodies using the measuring reagent of the present invention.
In addition to being capable of quickly diagnosing H., for example, in the process of producing antibodies by culturing lymphoid cells, it is extremely useful because antibodies can be easily measured without concentrating the culture fluid. The present invention will be explained in more detail with reference to Examples and Test Examples.
Not limited to NA antibodies, but anti-histone J'+'+
This also includes other types of anti-cough antibodies such as anti-cough antibodies, anti-SmK antibodies, and anti-RNP antibodies.
実施例1 不溶化ボ’) A D P −IJ g−ス
(不溶化抗原)
(1)固相担体の前処理
l穴あたD300blの容量を有する96大のプラスチ
ック製マイクロタイトレージ゛ヨンプレート(Dyna
tech社、Po1yvinylplateU型)を固
相担体として用いた。強陽電荷電のポIJ L −IJ
ジョン分子量:4X10’、シグマ社)を蒸留水に溶解
し濃度50μf/mlに調製した液を各穴100μtず
つ加え室温で1時間放置した後トリス−食塩緩衝液(2
5mM)リス、140mM食塩。Example 1 Insolubilized antigen) (1) Pretreatment of solid phase carrier A 96-sized plastic microtitration plate (Dyna
Polyvinylplate U type (manufactured by Tech Co., Ltd.) was used as a solid phase carrier. Strong positive charge Po IJ L -IJ
100 μt of a solution prepared by dissolving John Molecular Weight: 4×10', Sigma) in distilled water to a concentration of 50 μf/ml was added to each well, and left at room temperature for 1 hour, followed by Tris-salt buffer (2
5mM) Squirrel, 140mM NaCl.
pH7,4以下TBS と略称する)を用い4回洗浄し
た。The cells were washed four times using TBS (pH 7.4 or below).
(11) ポリADP−リポースの結合全弁らの方法
(Kanai、 Y−et al、 J−Bioche
m−。(11) Binding of polyADP-lipose by the method of Kanai, Y-et al., J-Bioche et al.
m-.
88.917〜920.1980)により製造したポリ
ADP−リボースをTBSを用い2μf/mtとなるよ
う濃度を調整した溶液を(1〕で得たマイクロタイトレ
ージョンプレートの各穴に50μtずつ加え37℃で一
夜を要して蒸発乾固させた後TBSで4回洗浄した。88.917-920.1980), the concentration of which was adjusted to 2 μf/mt using TBS, was added in an amount of 50 μt to each hole of the microtitration plate obtained in (1). The mixture was evaporated to dryness at °C overnight and washed four times with TBS.
(Iii) 後処理
(11)で得たプレ2トの抗原で満たされていない表面
を遮閉する目的で0.01%Ω牛血清アルブミンを添加
したTBSを各穴:300μtずつ加え1時間放置後T
BSで3回洗浄し不溶化ポIJ AD P −IJボー
ス(不溶化抗原)を得た。このものは加湿下4℃で1ケ
月は安定である。(III) In order to block the surface of the plate obtained in post-treatment (11) that is not filled with antigen, 300 μt of TBS supplemented with 0.01% Ω bovine serum albumin was added to each hole and left for 1 hour. Back T
The plate was washed three times with BS to obtain insolubilized poIJ ADP-IJ Bose (insolubilized antigen). This product is stable for one month at 4°C under humidification.
実施例2 不溶化二本鎖DNA (不溶化抗原)市販の
仔牛胸線DNAをマーマーの方法(Mar−mur、
J−Mo1. Biol・、 3 + 208.196
1 )に従って除蛋白質精製した後、ストラー・パパリ
アンの方法(5tollar、 B、D、and Pa
palian、 M、、 J−CIin、 In−ve
st・、66.210〜219.1980)に従ってS
l−ヌクレアーゼ処理し、一本鎖DNAの部分を完全切
断する。次いでこのDNAを合弁らの方法(Kanai
、 Y−et al、 J、 Biochem、、 8
8.917〜92(L1980)に従ってハイドロキシ
アパタイトカラムにかけ0.2 Mのリン酸緩衝液(p
H6,8)で溶出される二本鎖DNAのみを採取した。Example 2 Insolubilized double-stranded DNA (insolubilized antigen) Commercially available calf thymus DNA was purified by the Mar-mur method.
J-Mo1. Biol・, 3 + 208.196
After protein removal purification according to 1), the protein was purified using the Stoller-Papalian method (5tollar, B, D, and Pa
palian, M., J-CIin, In-ve.
st., 66.210-219.1980)
Treat with l-nuclease to completely cleave the single-stranded DNA. This DNA was then extracted using the method of Kanai et al.
, Y-et al., J.Biochem,, 8
8.917-92 (L1980) and applied to a hydroxyapatite column in 0.2 M phosphate buffer (p
Only the double-stranded DNA eluted with H6,8) was collected.
この二本鎖DNAをさらKSI−ヌクレアーゼ処理し、
この段階ではもはや81−ヌクレアーゼで切断されない
ことを260 nmにおける紫外吸収で確かめた。This double-stranded DNA was further treated with KSI-nuclease,
It was confirmed by ultraviolet absorption at 260 nm that 81-nuclease was no longer cleavable at this stage.
その後、またノ・イドロキシアパタイトカラムにかけ上
記の方法で溶出させた二本鎖DNAを採取した、
このようにして得た二本鎖DNAをポリADP−リボー
スの代シに用いその他は実施例1と同様の方法に従い、
二本鎖DNAをマイクロタイトレージロンプレートに結
合せしめて不醇化二本鎖DNA(不溶化抗原)を得た。Thereafter, the double-stranded DNA eluted using the above-mentioned method was collected from the hydroxyapatite column again. Following the same method as
The double-stranded DNA was bound to a micro titre rayon plate to obtain an infusible double-stranded DNA (insolubilized antigen).
実施例3 アルカリフォスファターゼ・プロティンA結
合物(標識試薬)
仔牛小腸由来のアルカリフォスファターゼ(シグマ社製
品、Typ41 ) 1.9rlとプロティンA(ファ
ルマシア社製品)0.75mfを食塩加リン酸緩衝液(
リン酸IQmM、食塩140mM、pH7,4,以下P
BSと略記する)1mzK溶解した溶液をPBSに対し
て透析した後、グルタルアルデヒド(シグマ社製;濃度
25%)を終濃度02%となるように加え室温で2時間
かきまぜ結合を行った後、ゲル口過装置(Uetrog
el AcA 34充j[1,IX54cm)にかけア
ルカリフォスファターゼとプロティンAとの結合物を分
離し蛋白質として220 trf/mtの標識試薬10
m1を得た。Example 3 Alkaline phosphatase/Protein A conjugate (labeling reagent) 1.9 rl of alkaline phosphatase derived from calf small intestine (Sigma product, Type 41) and 0.75 mf of protein A (Pharmacia product) were added to a saline phosphate buffer (
Phosphate IQmM, salt 140mM, pH 7.4, below P
After dialyzing a solution containing 1mzK (abbreviated as BS) against PBS, glutaraldehyde (manufactured by Sigma; concentration 25%) was added to a final concentration of 02%, and the mixture was stirred at room temperature for 2 hours to perform binding. Gel sifting device (Uetrog)
Separate the combined product of alkaline phosphatase and protein A using el AcA 34 ml [1, IX 54 cm) and convert it into a protein using labeling reagent 10 at 220 trf/mt.
m1 was obtained.
この結合物の酵素比活性は蛋白質1mfあたシ200U
(基質25mMパラニトロフェニルフォスフェート、p
H9,5,37℃の測定条件下にて)であり、酵素単独
のそれが900〜l100Uであることから極めて活性
の高い標識試薬である。このものは牛血清アルブミン0
5%及び窒化ソーダ002%の存在下4℃で4ケ月以上
安定であった。The enzyme specific activity of this conjugate is 200U per mf of protein.
(Substrate 25mM paranitrophenyl phosphate, p
(under measurement conditions of H9, 5, 37°C), and the amount of the enzyme alone is 900 to 1100 U, making it an extremely highly active labeling reagent. This stuff has bovine serum albumin 0
It was stable for more than 4 months at 4° C. in the presence of 5% and 0.02% sodium nitride.
実施例4 アルカリフォスファターゼ・抗マウス免疫グ
ロブリン抗体結合物(標識試薬)抗マウス免疫グロブリ
ン(IfG+IfM)抗体(Tufts大学、S to
l far教授よシ供与された)をプロティンAの代り
に用い、実施例3と同様の方法に従い、アルカリフォス
ターゼ・抗マウス免疫グロブリン抗体結合物(標識試薬
)を得た。(収量tomt、蛋白質とし”C140nf
i’ml ) 。Example 4 Alkaline phosphatase/anti-mouse immunoglobulin antibody conjugate (labeling reagent) Anti-mouse immunoglobulin (IfG+IfM) antibody (Tufts University, Sto.
A conjugate of alkaline forsterase and anti-mouse immunoglobulin antibody (labeled reagent) was obtained in the same manner as in Example 3, using instead of protein A. (Yield tomt, protein “C140nf
i'ml).
参考例1 対照グレート
実施例1の(11)におけるポIJ A D P −I
JボースのTBS溶液の代シにTBSのみを用い、その
他は実施例1と同様の方法によりポIJ A D P
−IJボース(抗原)を結合しないマイクロタイトレー
ジョンプレートを得、対照プレートとして用いた。Reference Example 1 Control Grade Example 1 (11) POIJADP-I
PoIJADP was prepared in the same manner as in Example 1 except that only TBS was used instead of the TBS solution of JBose
- A microtitreion plate without binding IJ Bose (antigen) was obtained and used as a control plate.
試験例1 抗ポIJ A D P −IJボース抗体の
測定SLE、轡者および正常人の各血清中の抗ポIJ
AD P −IJボース抗体を測定した。Test Example 1 Measurement of anti-PoIJ ADP-IJ Bose antibody in serum of SLE, addicts and normal subjects
ADP-IJ Bose antibody was measured.
(1)第1反応(不溶化抗原と抗体との反応)実施例1
の方法によシ製造した不溶化ポIJ AD P −リボ
ース(不溶化抗原)の各穴に001%の牛血清アルブミ
ンを加えたTBSで20倍に希釈した非動化血清100
μLを加え、微振とう下、室温にて60分間インキュベ
ートした。(1) First reaction (reaction between insolubilized antigen and antibody) Example 1
Inactivated serum 100 diluted 20 times with TBS containing 001% bovine serum albumin was added to each well of the insolubilized poIJ ADP-ribose (insolubilized antigen) prepared by the method of
μL was added and incubated for 60 minutes at room temperature with slight shaking.
反応液を除去した後、プレートをTBSで4回洗浄した
。After removing the reaction solution, the plate was washed four times with TBS.
(11)第2反応(標識試薬゛との反応)実施例3の方
法で得たアルカリフォスターゼ・−ゼ・プロティンA結
合物(標識試薬)をTBSで100倍に希釈した液を第
1反応を終ったプレートの各穴K 100 pl加え、
室温で60分間インキュベートした。反応液を除去し、
プレートをTBSで4回洗浄した。(11) Second reaction (reaction with labeling reagent) The alkaline foster protein A conjugate (labeling reagent) obtained by the method of Example 3 was diluted 100 times with TBS for the first reaction. Add 100 pl to each well of the finished plate,
Incubated for 60 minutes at room temperature. Remove the reaction solution,
Plates were washed 4 times with TBS.
(iii) 第3反応(酵素基質反硲)及び測定2、
5 mMのハラニトロフェニルフォスフェートを2mM
のMグCt!を添加した5 0 mMカーボネート緩衝
液(pH9,5) 10mtに溶解した液を基質とし、
第2反応を終ったグレートの各穴に100 pl加え、
37℃で10分間反応させた後、この溶液100μtを
取り出し0. I Nのカセイソーダ水溶液400μt
に加えて酵素反応を止めた。(iii) Third reaction (enzyme substrate reaction) and measurement 2,
5mM halanitrophenyl phosphate to 2mM
MG Ct! The substrate was a solution dissolved in 10mt of 50mM carbonate buffer (pH 9,5),
Add 100 pl to each hole of the grate where the second reaction has finished,
After reacting at 37°C for 10 minutes, 100μt of this solution was taken out and 0.00μt was taken out. IN aqueous solution of caustic soda 400 μt
In addition, the enzymatic reaction was stopped.
得られた各穴の反応液500μtのそれぞれ410nm
Kおける紫外吸収を測定した。410 nm of 500 μt of the reaction solution in each well obtained.
The ultraviolet absorption at K was measured.
非特異反応に基ずく酵素活性を補正するため、参考例1
の方法で製造した対照プレートを不溶化抗原の代りに用
いその他は前記と同様にして第1、第2及び第3反応を
行い紫外吸収を測定した。In order to correct enzyme activity based on non-specific reaction, reference example 1
The first, second and third reactions were carried out in the same manner as above except that the control plate prepared by the above method was used in place of the insolubilized antigen, and the ultraviolet absorption was measured.
各血清について不溶化抗原を用いたときの紫外吸収よシ
対照グレートを用いたときの紫外吸収を減じたものを真
の抗体活性としこれを表1に示す。For each serum, the ultraviolet absorption when using the insolubilized antigen and the ultraviolet absorption when using the control grade were determined to be the true antibody activity, which is shown in Table 1.
SLE患者と正常人との測定値の間にはt−検定で、0
.001<P<0.01の有意差が認められた。A t-test showed that there was a difference of 0 between the measured values of SLE patients and normal people.
.. A significant difference of 001<P<0.01 was observed.
対照プレートを用いたときの紫外吸収を表2に示す。S
LE患者と正常人との間には差はなく、また非特異反応
も極めて少ないことが表1の正常人の測定値との比較よ
り明らかである。Table 2 shows the UV absorption when using the control plate. S
It is clear from the comparison with the measured values of normal subjects in Table 1 that there is no difference between LE patients and normal subjects, and non-specific reactions are extremely rare.
試験例2 抗二本鎖DNA抗体の測定
SLE患者及び正常人の各血清中の抗二本鎖DNA抗体
の測定を行なった。Test Example 2 Measurement of anti-double-stranded DNA antibodies Anti-double-stranded DNA antibodies in the serum of SLE patients and normal individuals were measured.
試験例1の不溶化ポIj A D P −リボースに代
えて実施例2の方法により製造した不溶化二本鎖DNA
を不溶化抗原に用い、その他は試験例1と同様の測定方
法により血清中の抗二本鎖DNA抗体を測定した。Insolubilized double-stranded DNA produced by the method of Example 2 in place of the insolubilized POIjADP-ribose of Test Example 1
The anti-double-stranded DNA antibody in the serum was measured using the same method as in Test Example 1 except that the anti-double-stranded DNA antibody was used as the insolubilized antigen.
測定結果を表3に示す。The measurement results are shown in Table 3.
”S L E患者と正常人との測定値の間にはt−検定
で0.001<P<0.01の有意差が認められた。``A t-test revealed a significant difference of 0.001<P<0.01 between the measured values of SLE patients and normal subjects.
試験例3 ハイブリドーマの産生ずる抗ポリADP−リ
ボース抗体の測定
マウス骨髄腫細胞5P210−AP−14とポリADP
−リボースで免疫したC3H/Heマウス牌細胞をアン
ドレジュルフスキーらの方法(Andrzejervs
ki 。Test Example 3 Measurement of anti-poly ADP-ribose antibody produced by hybridoma Mouse myeloma cells 5P210-AP-14 and poly ADP
-C3H/He mouse tile cells immunized with ribose were prepared using the method of Andrzejervsky et al.
ki.
C,Jr、 etat、 J−Immunol−、12
4,1499〜1502゜1980)によって細胞融合
を行った。得られたハイプリドーマ11株について、そ
の培養上清をと9濃縮せずに抗ボIJADP−リボース
抗体を標識試薬として実施例4の標識試薬を用い、その
他は試験例1と同様の方法によシ測定した。C, Jr. etat, J-Immunol-, 12
Cell fusion was carried out by the following method (4, 1499-1502, 1980). Regarding the obtained 11 hybridoma strains, the culture supernatant was not concentrated and the labeling reagent of Example 4 was used as the anti-vo IJADP-ribose antibody as a labeling reagent, but otherwise the method was the same as in Test Example 1. I measured it.
測定結果を表4に示す。表4に示すようにハイブリドー
マの産生するポIJADP−リボースを培養上清を濃縮
することなく直接に測定することができた。The measurement results are shown in Table 4. As shown in Table 4, polyJADP-ribose produced by hybridomas could be directly measured without concentrating the culture supernatant.
表1 血清中の抗ボ!JADP−リボース抗体、表2
対照プレートでの紫外吸収(A 41015μt)表3
血清中の抗二本鎖DNA抗体
、表4 ハイプリドーマの産生ずる抗ポリADP−リポ
ーース抗体
B 1001 0.045C901
0,840
D 601 0.250D
901 0.885D 902
0.050E 902
0.155F 503 0.86
0F 702 0.130F
801 0.115F 100
3 0.055G 1001
0.12、特許出願人
三井製薬工業株式会社
手続補正書(方式)
%式%
1、事件の表示
昭和56年特許願第150668号
2 発明の名称
抗核抗体測定用試薬
3 補正をする者
事件との関係 特許出願←人
4、補正命令の日付
昭和57年1月5日
5、補正の対象
明細書
別紙の通シTable 1 Antibodies in serum! JADP-ribose antibodies, Table 2
Ultraviolet absorbance (A 41015 μt) on control plate Table 3
Anti-double-stranded DNA antibodies in serum, Table 4 Anti-poly ADP-lipose antibody B produced by hybridoma 1001 0.045C901
0,840D 601 0.250D
901 0.885D 902
0.050E 902
0.155F 503 0.86
0F 702 0.130F
801 0.115F 100
3 0.055G 1001
0.12, Patent applicant Mitsui Pharmaceutical Industries, Ltd. Procedural amendment (method) % formula % 1. Indication of the case 1982 Patent Application No. 150668 2 Name of the invention Reagent for measuring antinuclear antibodies 3 Case made by the person making the amendment Relationship with Patent application ← Person 4, Date of amendment order January 5, 1980 5, Notification of attachment of specification subject to amendment
Claims (1)
において、測定対象で、ある抗核抗体の産生を惹起する
抗原をプラスチック担体に結合せしめた不溶化抗原と、
該抗原には特異反応釜せず測定対象である抗核抗体と特
異反応をする第二の抗体又はプロティンAに酵素を結合
せしめた標識試薬との組み合わせよシなることを特徴と
する抗核抗体測定用試薬A reagent for measuring anti-M antibodies by enzyme immunoassay includes: an insolubilized antigen in which an antigen to be measured that induces the production of a certain antinuclear antibody is bound to a plastic carrier;
An anti-nuclear antibody characterized in that the antigen does not have a specific reaction pot, but instead is combined with a second antibody that reacts specifically with the anti-nuclear antibody to be measured, or with a labeling reagent in which protein A is bound to an enzyme. Measurement reagent
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15066881A JPS5856694A (en) | 1981-09-25 | 1981-09-25 | Reagent for assay of antinuclear antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15066881A JPS5856694A (en) | 1981-09-25 | 1981-09-25 | Reagent for assay of antinuclear antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5856694A true JPS5856694A (en) | 1983-04-04 |
| JPH0440662B2 JPH0440662B2 (en) | 1992-07-03 |
Family
ID=15501862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15066881A Granted JPS5856694A (en) | 1981-09-25 | 1981-09-25 | Reagent for assay of antinuclear antibody |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5856694A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6488155A (en) * | 1987-06-22 | 1989-04-03 | Ruijiana State Univ Found The | Immunological inspection for detecting antibody against antigen |
| JPH0192660A (en) * | 1987-01-30 | 1989-04-11 | Nippon Dpc Corp | Measurement of anti-dna antibody value in biological liquid and kit therefor |
| JPH03167473A (en) * | 1989-11-08 | 1991-07-19 | Nippon Dpc Corp | Method and kit for measuring anti-dna antibody coupling activity |
| JPH03218462A (en) * | 1990-10-30 | 1991-09-26 | Nippon Dpc Corp | Method of measuring anti-dna value in biological liquid and measuring kit |
| WO2005040798A1 (en) * | 2003-10-29 | 2005-05-06 | Eisai Co., Ltd. | Method of diagnosing alzheimer’s disease |
| CN104007266A (en) * | 2013-02-27 | 2014-08-27 | 中国医学科学院基础医学研究所 | Application of antigen containing 6-N-methyllysine residue in preparation of reagents for auxiliary diagnosis of systemic lupus erythematosus |
-
1981
- 1981-09-25 JP JP15066881A patent/JPS5856694A/en active Granted
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0192660A (en) * | 1987-01-30 | 1989-04-11 | Nippon Dpc Corp | Measurement of anti-dna antibody value in biological liquid and kit therefor |
| JPS6488155A (en) * | 1987-06-22 | 1989-04-03 | Ruijiana State Univ Found The | Immunological inspection for detecting antibody against antigen |
| JPH03167473A (en) * | 1989-11-08 | 1991-07-19 | Nippon Dpc Corp | Method and kit for measuring anti-dna antibody coupling activity |
| JPH03218462A (en) * | 1990-10-30 | 1991-09-26 | Nippon Dpc Corp | Method of measuring anti-dna value in biological liquid and measuring kit |
| WO2005040798A1 (en) * | 2003-10-29 | 2005-05-06 | Eisai Co., Ltd. | Method of diagnosing alzheimer’s disease |
| CN104007266A (en) * | 2013-02-27 | 2014-08-27 | 中国医学科学院基础医学研究所 | Application of antigen containing 6-N-methyllysine residue in preparation of reagents for auxiliary diagnosis of systemic lupus erythematosus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0440662B2 (en) | 1992-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0201079B1 (en) | Delayed solid phase immunologic assay | |
| JP2626657B2 (en) | Methods and reagents for measuring antibodies | |
| US4347311A (en) | Enzyme immunoassay for determining antigen specific antibodies and test kit for carrying out this assay | |
| US4338094A (en) | Macroencapsulated immunosorbent assay technique | |
| JPS6095355A (en) | Method and device for detecting activation of complement path | |
| US4474878A (en) | Sandwich EIA for antigen associated with hepatitis | |
| NZ211366A (en) | Nucleic acid-protein conjugate for use in immunoassays | |
| JPH01254869A (en) | Measurement of substance allowed to bond immunologically and diagnosing agent | |
| US6362008B1 (en) | Generic signalling mechanism for detection of analytes | |
| JPH02276969A (en) | Reagent for simultaneously detecting different markers of hepatitis | |
| JPS6171360A (en) | Assay for simultaneously testing antigen and antibody in serum | |
| EP0381450B1 (en) | Assay for bone alkaline phosphatase | |
| NO810340L (en) | ULTRAFOELSOM ENZYMATIC RADIOMMUNO TEST METHOD | |
| JPH09504374A (en) | Immunoassay for detecting human autoantibodies | |
| JP3327488B2 (en) | Method of immunochemical measurement of the subject | |
| RU2065164C1 (en) | Diagnostic test-system for hepatitis virus a detection | |
| JPH0440662B2 (en) | ||
| WO1990010227A1 (en) | Method and diagnostic test kit for detection of anti-cardiolipin | |
| EP0308242B1 (en) | Agglutination assay | |
| JPS6224745B2 (en) | ||
| US20070082346A1 (en) | Homogeneous detection method | |
| WO2001011368A1 (en) | Method and reagent for assaying arthritis-associated melanotransferrin | |
| EP0322102A2 (en) | Methods of improved antigen capture assays and compounds therefor | |
| JP2001305137A (en) | Method for immobilizing and measuring specific complex | |
| JPH04286957A (en) | Gene detection method |